Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APG Tn-9mer
- Development stage
- Preclinical
- Lead developer
- Vaxil Bio
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
APG Tn-9mer is a therapeutic cancer vaccine candidate developed by Vaxil Bio. It is a synthetic glycopeptide consisting of a 9-amino acid peptide derived from the signal (leader) sequence of the MUC1 protein, which is glycosylated with the Tn antigen (N-acetylgalactosamine). MUC1 is a transmembrane glycoprotein that is overexpressed and aberrantly glycosylated in many cancers, including multiple myeloma and various solid tumors. Unlike traditional MUC1 vaccines that target the tandem repeat domain, APG Tn-9mer targets the highly conserved leader sequence, which is essential for protein trafficking and is present in all MUC1 isoforms. By incorporating the tumor-associated Tn carbohydrate, the vaccine is designed to induce a robust T-cell mediated immune response against malignant cells while overcoming the immune tolerance often associated with native MUC1 structures.
- Other names
- Tn-MUC1 9-merTn-MUC-1 9-merTn-MUC 1 9-merMUC1 leader sequence glycopeptideMUC-1 leader sequence glycopeptideMUC 1 leader sequence glycopeptide
02
Targets
Tn-MUC1 (Mucin 1 (Tn-glycoform))
Beyond the preview
Go deeper on APG Tn-9mer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APG Tn-9mer.